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Liver and kidney transplantation in children 
receiving cyclosporin A ·and steroids 
The new immunosuppressive agent. cyclosporin A. was used with low doses of steroids to treat eight 
patients undergoing hepotic transplantation and three patients undergoing cadaveric renal 
transplantation. Seven of the eight liver recipients are well. including one who was given two livers. 
The three kidney recipients. who had developed cytotoxic antibodies after previously rejecting grafts 
with conventional immunosuppressive therapy. have had good results despite conditions which usually 
preclude attempts at transplantation. The ability to control rejection effectively and safely without 
chronic high-dose steroid therapy may make the described therapeutic regimen valuable for pediatric 
recipients of whole organs. 
Thomas E. Starzl, M.D., Ph.D., * Shunzaburo Iwatsuki, M.D., 
J. Jeffrey Malatack, M.D., Basil J. Zitelli, M.D., 
J. Carlton Gartner, Jr., M.D., Thomas R. Hakala, M.D., 
J. Thomas Rosenthal, M.D., and Byers W. Shaw, Jr., M.D., 
Pittsburgh. Pa. 
CADAVERIC ORGAN TRANSPLANTATION in infants and 
children has been an unreliable and morbidity-laden 
undertaking. The ability to control rejection has been 
unpredictable with conventional immunosuppressive thera-
py including azathioprine and prednisone with or without 
anti-lymphocyte globulin. Even with "success" the fre-
quent need for high-dose steroid therapy has all too often 
degraded the quality of post-transplantation life. 
We report here an alternative method of immunosup-
pression with cyclosporin A and low doses of steroids that 
has been used in eight liver and three cadaveric kidney 
recipients who have been followed for 31h months to 1 'h 
years. Although the experience is small and the follow-up 
periods short, the results have made us believe that 
transplantation of a variety of organs will become a 
practical reality in larger numbers of pediatric health care 
centers. 
From the Departments of Surgery and Pediatrics. 
The University of Pittsburgh Health Sciences Center. 
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·Reprinl address: DeplUlmenl of Surgery. Univt:rlilyof 
PII/sburgh. 1084 Scaife Hall. School of Medicine. 
PillSburgh. PA 15261. 
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METHODS 
Case material. 
Liver recipients. The eight patients were O1~ to 16 years 
of age (Table I). Four had biliary atresia; of these, three 
had had one or more previous attempts at porticoenteros-
tomy (Kasai procedure), and the earlier operations made 
transplantation difficult. Other diagnoses are shown in 
Table I. 
Abbreviations used 
CyA: cyclosporin A 
DR: D-relatcd 
Donor selection was random in respect to the HLA A, B 
and D loci. Matches of the four antigens of the A and B 
loci averaged 1.0 ± 0.7 (SD), range 0 to 2. Two DR 
matches were present in one case, one match existed in two 
cases, and no matches were present in the other six 
donor-recipient combinations. 
In two instances, grafts were placed into recipients who 
had pre-existing anti-donor antibodies. In one (No.8) an A 
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Table I. Features of eight patients treated with orthotopic liver transplantation using cyclosporin 
A (CyA) and low doses of steroids 
Transplantation Major Initial biliary 
Patient Age (yr)/sex 
16/F 
2 8/F 
3 lO/F 
4* 23/4/ M 
5* 4/F 
6:\: 2 1/6/M 
7 10Y:!/M 
8 10 1/6/F 
'Required secondary revision. 
Diagnosis 
Budd-Chlan syn-
drome 
Byler disease 
Intrahepatic biliary 
atresia 
Biliary atresia 
Biliary atresia 
Biliary atresia 
Alpha-,-antitrypsin 
deficiency 
Congenital biliary 
cirrhosis 
tPlus intermittent hydrocortisone boluses. 
iPrcvious Kasai procedure(s). 
date 
8-23-80 
9-16-80 
9-28-80 
5-9-81 
5-29-81 
6-3-81 
6-24-81 
6-12-81 
7-4-81 
complications 
.. Cholangitis from re-
tained stent 
Hepatic artery 
thrombosis 
Disrupted biliary 
anastomosis 
None 
Respiratory distress 
syndrome; biliary 
obstruction 
Liver abscess; Can-
dida peritonitis 
None 
None 
construction 
Duct to duct· 
Duct to duct 
Duct to duct· 
Duct to Roux limb 
Gallbladder to Roux 
limb-
Gall bladder to 
Roux limb·; Duct 
to Roux limb 
Duct to duct 
Duct to duct 
Table II. Features of three patients who had cadaveric renal retransplantation using cyclosporin 
A (CyA) and steroids 
Patient Age (yr)/sex 
8 11/12 F 
2 13 516 F 
3 13 1/3 F 
Year and Jate 
of previous 
grafts 
1981, rejected 7 
days 
1978, rejected 1 yr 
1979, rejected 2 wk; 
1979 rejected 4 
wk 
Transplantation 
date 
6-18-81 
7-4-81 
9-6-81 
blood type donor provided a liver for a B type recipient. In 
the other (No.5). the serum of the recipient contained T 
warm cytotoxic antibodies that killed all the lymphocytes 
of the donor. 
Kidney recipients. The three girls had undergone one or 
two previous transplantations (Table II). After the failed 
initial transplantations. the sera of all three had developed 
T warm cytotoxic antibodies which reacted against the 
HLA matches 
(oj possible) 
four) 
3 
3 
Adverse 
immunologic 
factors 
Widely reacting T 
warm antibodies; 
negative cross-
match with stored 
sera 
Widely reacting T 
warm antibodies; 
positive cross-
match with stored 
sera 
Widely reacting T 
warm antibodies; 
positive cross-
match with stored 
sera 
Major 
complications 
None 
None 
None 
cells of more than 40, 95, and 95% respectively, of the 48 
lymphocyte donors who contributed to an antibody screen-
ing panel. The cytotoxic crossmatches of the recipients 
with their actual donors were negative using current sera, 
but in Patients 2 and 3 T warm crossmatches were positive 
with stored sera that had been collected a few weeks or 
months previously. In most centers the latter finding is 
considered a positive cross-match and precludes renal 
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Bilirubin 
Img) 
6 
Died 19 days 
< I 
< I 
< I 
< I 
<I 
< I 
Present 
creatinine 
Img/dl) 
t.3 
1.7 
1.1 
Present daily drug doses 
CyA 
Img/kg) 
10 
7.2 
9 
5.5 
9.3 
8 
9.3 
Prednisone 
(mg) 
lot 
10 
5 
5 
5 
3.5 
5 
Present daily drug doses 
CyA 
Img/kg) 
10 
9 
10 
Prednisone 
(mg) 
7.5 
15 
15 
transplantation. One to three HLA antigens were matched 
(Table II). No DR antigen matches were found between 
any of the donors and recipients. 
The operations. 
Liver transplantation. Two of the nine donor livers were 
obtained locally, and the other seven from cities 300 to 
2,000 miles away. The hepatic grafts were preserved with 
Collin's solution I and transplanted by previously described 
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Fig. I. Uncomplicated recovery after liver transplantation. The 
2¥..-year-old patient had biliary atresia. Note the low doses of 
prednisone which were used after an initial period of high intensity 
treatment. 
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rig. 2. Recovery after liver transplantation of a 1011z-year-old 
patient who developed transient nephrotoxicity from cyclosporin 
A. Note the five-day switch from cyclosporin A to azathioprine 
therapy. The original diagnosis was alpha I-antitrypsin deficien-
cy. 
techniques2.l after one to 101h hours of cold ischemia. 
Antibiotics were given prophylactically and for a few days 
postoperatively. Subsequent antibiotic therapy was given 
for specific indications only. 
Kidney transplantation. The kidneys were preserved 
with asanguinous perfusion or with Collin's solution and 
transplanted by conventional techniques4 approximately 
one day after their removal. 
684 StaTZI et aJ. 
'" z 
KIDNEY TRANIIJIUNT 
8 VEAR OLD 9 
23-21 kg 
~~ .. ~ ~r 6 
OISCHAllQE j 
u 2 ~ 
5 
f ~~~--------------------------~ 
'00 
~ eo 
~- eo zr s- 4Q 
if .., 
10 15 2Q 25 JO 
TIME IN DAYS 
R-GRAFT fIIAOIATtON "SO R) 
S.H'fDROCORTISONE UiOO mg F.'/.I 
60 90 120 150 
Fig. 3. Recovery after renal retransplantation under immunosup-
pression with cyclosporin A and prednisone. The second burst of 
prednisone therapy was necessitated by an acute rejection. but 
within five months the patient's prednisone dose had been reduced 
to 7.S mgjday. 
IIIIIIIUDe suppression. Combination therapy with CyA 
and steroids has been described previously.s.9 
Liver recipients. CyA was started four to six hours 
before operation with a single oral dose of 17.5 mg/kg. 
Afterward the same daily dose was continued intramuscu-
larly or orally as soon as diet was resumed (Figs. 1 and 2) 
but with half the total amount in the morning and the other 
half in the evening. The daily dose was reduced if nephro-
toxicity or other side effects were suspected (Fig. 2). All 
surviving patients are still receiving CyA. 
Intravenous prednisone or hydrocortisone therapy was 
begun intraoperatively and converted afterward to the oral 
route as soon as possible. Postoperatively, patients who 
were in reasonable physiologic condition were given a 
five-da.y burst of prednisone (Figs. 1 and 2) beginning at 
60 to 100 mg/day (depending on weight) and ending with 
maintenance doses of 5 to 20 mg/day. The steroid burst 
was omitted in those liver recipients who were gravely ill at 
the time of operation; they were given 10 to 20 mg/day. 
Further steroid weaning was variable. If rejections super-
vened, these were treated with boluses of hydrocortisone, 
0.3 to 1.0 gm intravenously. 
Kidney recipients. Immunosuppressive therapy (Figs. 3 
and 4) was similar to that after liver transplantation except 
that steroids were used more liberally at the outset.5.6.8.9 In 
two of the kidney recipients, a second five-day burst of 
high dose steroid therapy was given (Fig. 3). 
RESULTS 
Urer transplantation. 
Survival. One of the eight liver recipients died after 19 
days. The homograft hepatic artery had thrombosed. The 
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Fig. 4. Renal transplantation in a l3-year-old girl who had 
previously rejected two grafts. Subsequently she developed widely 
reactive T warm antibodies (to 99% of the popUlation) making her 
a noncandidate for transplant. Eventually a kidney was obtained 
from a donor against whose lymphocytes the current recipient 
serum did not react, although stored serum still gave a positive 
crossmatch. The transplanted kidney survived the immediate 
immunologic insult and began to function within two weeks. She 
has had a good result. 
death was ascribed to surgical error although no obvious 
technical mistake could be found at the anastomosis. The 
other patients have lived for 6 to 16th months. All are at 
home. 
Liver function. All but one of the surviving patients has 
a serum bilirubin concentration less than 1.0 mg/ dl (Table 
I). The exceptional patient developed jaundice one year 
postoperatively with a peak bilirubin concentration of 58 
mg/dl. Eventually, a retained stent in the reconstructed 
common duct was removed at reoperation. In the succeed-
ing four months, the bilirubin concentration has slowly 
fallen to its present level of 6 mg/dl. Other liver function 
tests of the survivors have been normal or near normal 
except for persistent low-grade elevations of serum trans-
aminases or alkaline phosphatase in the exceptional patient 
described above. 
Retransplantation. One of the seven surviving patients 
(No.6, Table I) developed a huge abscess of the right 
hepatic lobe which contained a variety of bacteria as well 
as Candida albicans. After two weeks the damaged liver 
was replaced with a fresh homograft. The boy had a 
stormy postoperative course, but recovered completely. 
Biliary tract reconstruction. Five of the nine livers in the 
eight patients had bile duct reconstruction with duct-
to-duct anastomosis (Table I). In one case, an anastomotic 
disruption necessitated reoperation and conversion to cho-
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ledochojejunostomy with a Roux-en-Y jejunal limb. Late 
secondary operation for stent removal was necessary in 
another recipient. 
Biliary reconstruction of two livers was satisfactory by 
primary Roux-en-Y choledochojejunostomy. The two final 
livers were reconstructed by anastomosing the graft gall-
bladder to a Roux limb (cholecystojejunostomy). One 
required conversion to choledochojejunostomy. The other 
liver was removed at retransplantation (Patient 6). Defec-
tive biliary drainage may have contributed to the destruc-
tion of this liver (see previous section). 
Other major complications. Early deterioration of renal 
function occurred in two patients. both of whom had 
received nephrotoxic antibiotics as well as CyA. The most 
severe example is shown in Fig. 2. The complication was 
treated by a reduction of CyA dosage. and in one instance 
(Fig. 2) by omitting the dose of CyA for several days and 
substituting azathioprine; dialysis was not required. One 
patient (No.5) had severe pulmonary edema and paralysis 
of the right phrenic nerve. requiring ventilatory support for 
three weeks. Patient 6 had recurrent laryngeal nerve 
paralysis. 
Maintenance drug therapy (Table I). The ability to use 
low maintenance doses of prednisone was noteworthy. In 
past experience with conventional immunosuppression. the 
single most important determinant of the quality of life 
following liver transplantation has been the requirements 
for steroid therapy.l.IO 
Hospitalization. The days in hospital after transplanta-
tion of the seven survivors averaged 56 ± 34 (SO) and 
ranged from 18 to 93. With conventional immunosuppres-
sive therapy, patients with what were then considered to be 
favorable courses spent an average of nearly five months of 
the first postoperative year in the hospital. and those with 
protracted survival despite troubled courses spent more 
than six months of the first postoperative year in the 
hospitaJ.1O 
Renal transplantation. The two patients whose recently 
stored sera had positive T warm crossmatches with their 
•• donors had a short-lived postoperative diuresis followed by 
oliguria for two and three one-half weeks, respectively, 
requiring temporary dialysis support (Fig. 4). They recov-
ered completely. 
The third patient had a severe but quickly reversible 
rejection after six days (Fig. 3). Hospitalization was 
required for 23, 38, and 24 days. The serum creatinine 
concentration in all three patients is below 2.0 mgjdl 
(Table II). Follow-up has been 4 to 6\.7 months. 
DISCUSSION 
When renal transplantation was made feasible by the 
combined use of azathioprine and prednisone.4 there were 
expressions of concern about subjecting pediatric recipi-
ents to such drastic therapy. II However. the first report of 
consistent success in treating infants and children4• 12 was 
promptly confirmed,ll·16 although acceptable results were 
obtained only with consanguineous donors. A number of 
special pediatric transplantation centers were estab-
lished.l7•20 at which there usually has been a major effort to 
find genetically related donors. Failure to do so and 
consequent transplantation of cadaveric kidneys has been 
associated with a higher incidence of graft loss, death. and 
unacceptable morbidity from chronic high-dose steroid 
therapy. With organs such as the liver, there has been no 
option to the use of cadaveric donors. Major progress in 
cadaveric transplantation has been stalled for almost two 
decades despite efforts at tissue typing, better understand-
ing of rejection. and modest improvements in immunosup-
pression made possible by adding antilymphoid globu-
lins2. 16.21 or thoracic duct drainage to the original 
azathioprine-prednisone therapy. 
Thus the description by Borel et ap2.2J of a fungus 
extract, cyclosporin A. which was a powerful immunosup-
pressant. and news of its first encouraging trials by Caine 
et aP4.25 were major and long awaited events. The drug 
became available for clinical testing in the United States in 
late 1979. Our consequent experience with CyA, for 
kidney and liver transplantation. and our recommenda-
tions about its use with conservative doses of steroids have 
been reported and are based principally upon observations 
in adults. 5·9 
In spite of the superior results obtained when CyA is 
used alone24-27 or in combination with low-dose steroids.5.9 
the agent has not been available for evaluation in patients 
under 18 years of age because of the unknown risks from 
side effects. The initial fear that there might be an 
exorbitant incidence of de novo lymphomas25 has proved 
unfounded.7.8 Nephrotoxicity, hepatotoxicity, hirsutism. 
motor dyskinesias. and gum hyperplasia have been man-
ageable by dose adjustments.7.26 
Cyclosporin A was released on a compassionate basis to 
our pediatric liver recipients after it had become apparent 
that the chance of survival in adults after hepatic replace-
ment was nearly doubled with use of the drug.' The same 
benefit has been seen in the children receiving livers. of 
whom seven of eight are alive after six to 16\.7 months. The 
pediatric recipients were by no means free of the compli-
cations that have plagued efforts at liver transplantation in 
the past, but with the good control of rejection achieved 
with low-dose steroid therapy, these complications (includ-
ing retransplantation in the face of an otherwise lethal 
infection in the first graft) could be managed. 
Cyclosporin A was released compassionately to the three 
kidney recipients for equally forceful reasons. These 
patients were having problems with dialysis. Under the 
best of circumstances, retransplantation has a lowered 
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graft survival, and a one-year mortality that has been as 
high as 40%.28 In addition, with the presence of widely 
reacting T warm antibodies in their sera, our patients had 
even pllOl'er prospects of successful cadaveric renal retrans-
plantation; in most centers, they would have been consid-
ered noncandidates for such an heroic effort. Two of the 
three patients had been waiting for more than three years 
for a cadaveric kidney. Although severe immunologic 
reactions ensued postoperatively, necessitating brief con-
tinuation of dialysis for two of the three recipients, all three 
have had a good result and have not required excessive 
steroid therapy. 
Caution is justifiable in restricting the use of new 
techniques and drugs to adults during their developmental 
phase. However. pediatric recipients whose growth and 
development patterns are severely inhibited by convention-
al immunosuppression with high doses of steroids should 
benefit most from CyA therapy when it is released for 
more general use. In our liver and kidney recipients. the 
plan is to reduce the maintenance prednisone doses even 
lower than the present level. 
Randomized controlled trials comparing cyclosporin A 
and steroid therapy with conventional immunosuppression 
for renal transplantation in adults are underway in a 
number of centers. including our own. The results of these 
trials should be applicable in making decisions about 
treatment 'P'I'otocols for infants and children. 
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